Point6 Bio

Company Overview

Snapshot

Founded in January 2023 by Neta Barashi, Point6 Bio operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing its core technology.

Business overview

Point6 Bio is a computational biology company specializing in biomarker-based analysis for the diagnosis of Autism Spectrum Disorder (ASD). The company's platform integrates advanced AI with multi-omic data, including insights from the proteome and gut microbiome, to detect molecular changes underlying neurodevelopmental disorders. By decoding proteomic and post-translational modification (PTM) patterns from blood samples, Point6 Bio aims to identify reproducible, disease-specific biomarker signatures for early and reliable diagnosis, ultimately transforming ASD care and identifying new drug targets. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Digital Medical Diagnostics.

Company Intelligence Q&A

What is Point6 Bio's primary focus?

Point6 Bio is a computational biology company focused on biomarker-based analysis for the diagnostics of Autism Spectrum Disorder (ASD).

When was Point6 Bio founded?

Point6 Bio was founded in January 2023.

Who is a co-founder of Point6 Bio?

Neta Barashi is a co-founder and CEO of Point6 Bio.

What technology does Point6 Bio utilize?

Point6 Bio's platform integrates advanced AI with multi-omic data to detect molecular changes underlying neurodevelopmental disorders.

What is the goal of Point6 Bio's platform?

The platform aims to identify reproducible, disease-specific biomarker signatures from simple blood samples to enable early, reliable diagnosis of Autism Spectrum Disorder.